[go: up one dir, main page]

ATE165511T1 - Behandlung von organtransplantatsabstossung - Google Patents

Behandlung von organtransplantatsabstossung

Info

Publication number
ATE165511T1
ATE165511T1 AT91910880T AT91910880T ATE165511T1 AT E165511 T1 ATE165511 T1 AT E165511T1 AT 91910880 T AT91910880 T AT 91910880T AT 91910880 T AT91910880 T AT 91910880T AT E165511 T1 ATE165511 T1 AT E165511T1
Authority
AT
Austria
Prior art keywords
treatment
organt
transplant rejection
fluoro
carboxylic acid
Prior art date
Application number
AT91910880T
Other languages
English (en)
Inventor
Neil Richard Ackerman
Bruce Donald Jaffee
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Application granted granted Critical
Publication of ATE165511T1 publication Critical patent/ATE165511T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT91910880T 1990-06-11 1991-06-05 Behandlung von organtransplantatsabstossung ATE165511T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/535,672 US5204329A (en) 1990-06-11 1990-06-11 Treatment of organ transplantation rejection

Publications (1)

Publication Number Publication Date
ATE165511T1 true ATE165511T1 (de) 1998-05-15

Family

ID=24135268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91910880T ATE165511T1 (de) 1990-06-11 1991-06-05 Behandlung von organtransplantatsabstossung

Country Status (14)

Country Link
US (1) US5204329A (de)
EP (1) EP0537191B1 (de)
JP (1) JPH05507697A (de)
KR (1) KR930700107A (de)
AT (1) ATE165511T1 (de)
AU (1) AU664354B2 (de)
CA (1) CA2085002A1 (de)
DE (1) DE69129332T2 (de)
DK (1) DK0537191T3 (de)
ES (1) ES2114888T3 (de)
IE (1) IE911962A1 (de)
IL (1) IL98425A (de)
WO (1) WO1991019498A1 (de)
ZA (1) ZA914456B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06116151A (ja) * 1991-08-06 1994-04-26 Asahi Chem Ind Co Ltd 増殖性皮膚疾患治療用組成物
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US5409886A (en) * 1993-02-18 1995-04-25 Mitsui Toatsu Chemicals, Incorporated 3-pyrroline-2-one derivatives and herbicidal compositions containing same
US6171585B1 (en) 1993-05-14 2001-01-09 Cedars-Sinai Medical Center IVIg immunosuppression in HLA-sensitized transplant recipients
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US5578609A (en) * 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
US5627193A (en) * 1995-02-09 1997-05-06 Mitsui Toatsu Chemicals, Inc. Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
AU2896097A (en) * 1996-05-10 1997-12-05 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
KR20010014030A (ko) 1997-06-19 2001-02-26 더글라스이.리디치 퀴놀린-인돌 항균제, 이들의 용도 및 조성물
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
AU2108099A (en) * 1998-01-30 1999-08-16 Procept, Inc. Immunosuppressive agents
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
AU2859499A (en) * 1998-03-27 1999-10-18 Chong Kun Dang Corporation (streptomyces) sp. producing tautomycetin and immunosuppressant comprising tautomycetin as active ingredient
US7323471B1 (en) * 1999-08-13 2008-01-29 Dor Biopharma, Inc. Topical azathioprine for the treatment of oral autoimmune diseases
WO2015077535A2 (en) 2013-11-22 2015-05-28 Genzyme Corporation Novel methods for treating neurodegenerative diseases
CN106061506A (zh) * 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
US11406707B2 (en) * 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
FI3875459T3 (fi) 2015-10-30 2024-02-14 Neurocrine Biosciences Inc Valbenatsiinin dihydrokloridisuoloja ja niiden polymorfeja
HUE059065T2 (hu) 2015-12-23 2022-10-28 Neurocrine Biosciences Inc Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására
AU2017395703B2 (en) 2017-01-27 2021-09-23 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP7250006B2 (ja) 2017-09-21 2023-03-31 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2019322863B2 (en) 2018-08-15 2025-02-27 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6592M (de) * 1967-10-31 1968-12-30
GB1334705A (en) * 1970-06-19 1973-10-24 Ici Ltd Pharmaceutical compositions containing kynurenic acid derivatives
CH576445A5 (de) * 1972-03-10 1976-06-15 Ciba Geigy Ag
DE2449030A1 (de) * 1974-10-11 1976-05-20 Schering Ag Neue pyridin-derivate
US4407803A (en) * 1981-08-17 1983-10-04 Abbott Laboratories Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
FI75308C (sv) * 1985-01-25 1988-06-09 Ky Carlson Project Kb Hydrostatiskt drivsystem.
US4625034A (en) * 1985-02-04 1986-11-25 Usv Pharmaceutical Corp. 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4661499A (en) * 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines
GB8602372D0 (en) * 1986-01-31 1986-03-05 Sandoz Ltd Organic compounds
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US4968701A (en) * 1988-04-26 1990-11-06 E. I. Du Pont De Nemours And Company 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
US4861783A (en) * 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
DE3814504A1 (de) * 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
EP0537191B1 (de) 1998-04-29
AU664354B2 (en) 1995-11-16
US5204329A (en) 1993-04-20
IE911962A1 (en) 1991-12-18
CA2085002A1 (en) 1991-12-12
KR930700107A (ko) 1993-03-13
DK0537191T3 (da) 1998-10-07
IL98425A (en) 1995-06-29
AU8087391A (en) 1992-01-07
DE69129332D1 (de) 1998-06-04
JPH05507697A (ja) 1993-11-04
DE69129332T2 (de) 1998-08-27
EP0537191A1 (de) 1993-04-21
ZA914456B (en) 1993-02-24
EP0537191A4 (en) 1993-08-11
WO1991019498A1 (en) 1991-12-26
ES2114888T3 (es) 1998-06-16

Similar Documents

Publication Publication Date Title
ATE165511T1 (de) Behandlung von organtransplantatsabstossung
DK0484281T4 (da) Cyclosporiner
TR199801919T2 (xx) Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
NO961345L (no) O-aryl, O-alkyl-, O-alkenyl- og O-alkynylmakrolider med immunundertrykkende aktivitet
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
DE3884200D1 (de) Verfahren zur Behandlung von Mastitis und anderen Staphylokokkeninfektionen.
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
DE69435303D1 (de) Er behandlung von krankheiten bei denen eine cytok
MY106038A (en) 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents.
AU8216691A (en) Autobiotics and their use in eliminating nonself cells in vivo
FI931204A0 (fi) Nya, saosom lipooxigenasinhibitorer verkande aminobensosultamderivat
DE3875306D1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
CA2060474A1 (en) Pharmaceutical use
ES2078462T3 (es) Esteres de castanoespermina anti-herpes.
BG93298A (bg) Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни
DE60045638D1 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
EA199900363A1 (ru) Новые производные пентаэритрита, их получение и применение, а также промежуточные продукты для их синтеза
DE59101882D1 (de) Inhibitor der proliferation von endothelzellen.
EP0653208A3 (de) Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
RU97117419A (ru) Эндопротез голеностопного сустава
FR2656199B1 (fr) Compositions fongicides ternaires pour le traitement du mildiou de la vigne.
FR2669539B1 (fr) Dispositif pour la circulation artificielle du sang et transfuseur autologue de sang total.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee